|
Synonyms: compound ID 344 [ WO2023118263] | neurokinin A (4-10)-S5K/F6Y/L9mL/M10Mox | SEQ ID NO: 23 [WO2023118263]
Compound class:
Peptide
Comment: EB1002 is a seven amino acid, chemically modified analogue of neurokinin A (NKA). It is reported as a NK2R selective agonist [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||
| References |
|
1. Ekberg JH, Christensen DP, Hansen JB. (2023)
Agonists for treatment of eating disorder. Patent number: WO2023118263A1. Assignee: Embark Biotech ApS. Priority date: 21/12/2022. Publication date: 29/06/2023. |
|
2. Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña MG, Dollet L, Brown JM, Basse AL, Yacawych WT, Burm HB et al.. (2024)
NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature, 635 (8040): 987-1000. [PMID:39537932] |